Home / COVID-19 / Research Agency Funding

Research Agency Funding

Funding opportunities and resources regarding COVID-19. Contact cfr@ucsc.edu for any foundation or corporate opportunities. For all other inquiries contact resdev@ucsc.edu.


Sponsors and program information
Sponsor Program Title Identifier Description Deadline Funding Area
NIH Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding Current and comprehensive coronavirus updates
NIH NIH Funding Opportunities Specific to COVID-19 Comprehensive NIH Funding Opportunities.
NIH Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects NOT-AI-21-002 to highlight the critical need to develop prophylactic vaccines able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. Rolling until 7/12/21 Vaccine Devleopment
NIH NIAID, Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) PAR-20-177 High Priority Areas: critical aspects of viral infection, replication and pathogenesis, critical aspects of viral transmission, identification and characterization of the onset and duration of immunity, virologic and serologic surveillance studies and natural history studies to understand the origin of the virus, assess and characterize the natural history and long-term consequences of SARS-CoV-2 infection, clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity, specificity and ability to provide rapid results, development of SARS-CoV-2-specific or broadly protective coronavirus vaccine candidates, inform the development of vaccination strategies for at-risk populations, development of assays and animal models, assess animal models for SARS-CoV-2 and how the models compare to human infection, development of animal models for transmission experiments, development of organoid culture models and/or ex vivo explant models, computational modeling studies to identify and evaluate interventions to protect at-risk populations and for making public health policy decisions, interactions and impact between SARS-CoV-2 and other respiratory pathogens, comparative studies of SARS-CoV-2 to other coronaviruses, and ata science approaches to develop algorithms, models, and informatics solutions. rolling through 04/30/2021 many
NIH Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) PAR-20-178 High Priority Areas: critical aspects of viral infection, critical aspects of viral transmission, identification and characterization of the onset and duration of immunity, virologic and serologic surveillance studies and natural history studies to understand the origin of the virus including the animal host reservoir, potential intermediate hosts, factors leading to spill over events, evidence of continued spill over events and studies at the human-animal interface, assess and characterize the natural history and long-term consequences of SARS-CoV-2 infection in various human populations, development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity, specificity and ability to provide rapid results, development and testing of SARS-CoV-2 therapeutic candidates, in relevant in vitro, ex vivo or animal models, development of SARS-CoV-2-specific or broadly protective coronavirus vaccine candidates, studies to inform the development of vaccination strategies for at-risk populations, development of assays and animal models, development of assays and animal models, development of animal models for transmission experiments, development of organoid culture models and/or ex vivo explant models, computational modeling studies to identify and evaluate interventions to protect at-risk populations and for making public health policy decisions, interactions and impact between SARS-CoV-2 and other respiratory pathogens, comparative studies of SARS-CoV-2 to other coronaviruses, data science approaches to develop algorithms, models, and informatics solutions. rolling through 04/30/2021 many
NIH Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), PA-20-135 PA-20-135 See "Components of Participating Organization" for participating IC's and "Related Notices" Notice of Special Interest (NOSI) announcements for specific research/program interests. Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA. See IC Emergency Notice of Special Interest (NOSI) many
NIH Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional), PA-18-935
 PA-18-935 See "Components of Participating Organization" for participating IC's and "Related Notices" Notice of Special Interest (NOSI) announcements for specific research/program interests. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA. See IC Emergency Notice of Special Interest (NOSI) many
NIH Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-20-272
 See "Components of Participating Organization" for participating IC's and "Related Notices" Notice of Special Interest (NOSI) announcements for specific research/program interests. You must have an existing award from relevant IC. See IC website many
NIH Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 NOT-GM-20-025 (1) Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). (2) Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only). (3) Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only). 3/25/20 through 2/5/21 Predicitive Models, Diagnostics, and Therapeutics
NIH NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) NOT-ES-20-015 To understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. 5/4/21 Transmission & Prevention
NIH NIEHS, Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed), RFA-ES-19-011 RFA-ES-19-011 The goal of the program is to characterize initial exposures, collect human biological samples, or collect human health and exposure data in order to provide critical information to understand exposure-health outcome relationships, with the goal of providing data that will facilitate timely action to protect public health." The 2-year project period may not exceed $275,000. Proposals accepted monthly on the first of the month. monthly through Oct. 2022
 Environmental Health
NIH Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) PA-20-172 To invite robust investigative and collaborative research focused on understanding the long-term effects of disasters on health disparity populations and the health care systems that serve them, including the influence of risk factors or vulnerabilities of both the systems and the communities preceding the event(s). Standard dates through Sept. 2023
 Healthcare Systems & Disasters
NIH Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional) PAR-20-243 To focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations. 3/2/21
 Digital Health Interventions
NIH POCTRN Fast-Track Program for COVID-19 Test Development and Distribution PAR-17-453 Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing. NIBIB is urgently soliciting proposals to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). continued until further notice
 Rapid Testing
NIH Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders NOT-DC-20-008 There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Varies by opportunity Healthcare
NIH Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA NOT-AA-20-011 Research is needed to understand the potentially complex relationships between alcohol consumption and COVID-19 related-outcomes to enhance the nation’s response to the current pandemic. The outcomes include overt pathophysiology and the impact of social and policy measures on COVID-19 outcomes. 5/15/21 Healthcare
NIH Notice of Special Interest (NOSI) – Research on Rehabilitation Needs Associated with the COVID-19 Pandemic NOT-HD-20-031 To encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: (1) Encourage research to address the rehabilitation needs of survivors of COVID-19. (2) Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions. (3) Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities 2/15/21 through 5/8/23 Rehabilitation and Mitigation
HHS Addressing Racial and Ethnic Disparities to Improve Health Outcomes MP-CPI-21-003 Awardees will: (1) Obtain governmental and public buy-in for engaging in this policy collaborative endeavor; (2) Create a multi-sector team (e.g., comprised of leadership from the governor's/mayor's office and health, behavioral health, child welfare, justice, education, commerce, community service and other agencies, and from community organizations); (3) Conduct a review of existing policies to identify the areas primed for a structural racism assessment; (4) Develop or revise a policy (or policies) to address structural racism and improve health outcomes; (5) Implement the new/revised policy and evaluate its impact on health outcomes for racial and ethnic minorities within their jurisdiction; and (6) Create and implement strategies to communicate, sustain and spread policies resulting in improved health outcomes for racial and ethnic minorities. 3/31/21 Addressing Structural Racism in Health Policies
HHS Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services to Mitigate Morbidity and Mortality RFA-GH-21-004 To understand the needs of emergency-affected and displaced populations by improving epidemiological methods, estimating morbidity and mortality of these populations during COVID-19, as well as understand the specific health sector needs of persons affected by humanitarian/public health emergencies and best practices for improving health outcomes. 2/18/21 Epidemiology & Public Health
HHS BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement BAA-20-100-SOL-0002 Molecular diagnostic assay for SARS-CoV-2 virus on existing FDA-cleared platform, Point-of-care diagnostic assay for detection of SARS-CoV-2 virus, Diagnostic assay for detection of COVID-19 disease, Nonclinical model development and screening for SARS-CoV-2 virus, Alternate vaccine delivery/administration and adjuvants, and Advanced manufacturing technologies. Rolling Diagnostics
HHS Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services to Mitigate Morbidity and Mortality RFA-GH-21-004 To understand the needs of emergency-affected and displaced populations by improving epidemiological methods, estimating morbidity and mortality of these populations during COVID-19, as well as understand the specific health sector needs of persons affected by humanitarian /public health emergencies and best practices for improving health outcomes. 2/18/21 Public Health
NSF Coronavirus Information Current and comprehensive coronavirus updates. DCL NSF 20-052 has been archived. NSF encourages PIs to explore existing funding opportunities across NSF and to contact the cognizant NSF Program Officers for relevant programs; NSF remains open to inquiries concerning COVID-19 research in response to existing programs.
CDC Strengthening Public Health Research and Implementation Science (Operations Research) to Control and Eliminate Infectious Diseases Globally RFA-GH-21-006 (1) Conduct and monitor epidemiologic and laboratory-based science, surveillance, and research related to COVID-19 and other global public health threats in Africa, Southeast Asia, Eastern Europe and Central Asia, and the Middle East and North Africa (MENA), (2) Incorporate the results of these public health activities into operational disease detection, prevention, and response or control programs in regions noted above, strengthen public health capacity 2/22/21 Global Public Health
DHS Frequently Asked Questions for DOD Research Proposers and Awardees Impacted by the Novel Coronavirus (COVID-19) Therapeutics
DOD Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing W911QY-20-S-0019 This Prototype project is a combination of an agile development activity, design, and demonstration of the technical and operational utility of a product to move forward to FDA licensure/approval. 2/28/21 Therapeutics
DOE Office of Science Director Dear Colleagues Letter Soliciting "scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure.
University of California UC MEXUS SUPPLEMENTAL COVID-19 FUNDING OPPORTUNITY UC MEXUS (ucmexus.ucr.edu) supplemental funding opportunity for UC faculty undertaking research on COVID-19 who want to engage with Mexico. Bi-national collaboration
CIRM Special Call for COVID-19 Projects COVID-19 To support promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments to COVID-19 patients in need. CIRM has established an open call for proposals and will accept applications on a bi-monthly basis. Rolling deadline, every 2 months Treatments
Gates Foundation COVID-19 Therapeutics Accelerator Announcement Bill & Melinda Gates Foundation, Wellcome, and Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19. Therapeutics
Bill & Melinda Gates Foundation/ ICODA Grand Challenges ICODA COVID-19 Data Science pilot programme To support projects that harness the power of health data in a safe and trusted way to
respond to the current COVID-19 pandemic and have impact, as well as to enhance global health data responses to health challenges of the future. It also seeks to involve patients and wider communities in both study design and governance.		 1/19/21 Global health data
Ford Foundation + many Five Foundations Commit $1.7+ Billion to Nonprofit Organizations in Wake of Pandemic Doris Duke Charitable Foundation, Ford Foundation, W.K. Kellogg Foundation, the John D. & Catherine T. MacArthur Foundation, and the Andrew W. Mellon Foundation announced a joint commitment to increase their payouts to nonprofit organizations with more than $1.7 billion within the next three years to help stabilize and sustain a nonprofit sector facing devastating economic effects due to the global pandemic and the epidemic of social injustice.
Ford Foundation + many Families and Workers Fund The Families and Workers Fund is an opportunity to not just recover and return to business-as-usual, but to also build a stronger, more equitable society where there is greater economic security, opportunity, and work with dignity for all. Target areas include Direct Relief and Centering Vulnerable Workers and Families in the Economic Response to COVID-19 See funder for updates Social Sciences, Humanities, Economics
Bloomberg Philanthropies Coronavirus Global Response Initiative & Local Response Initiative This global initiative will support immediate action to prevent or slow the spread of COVID-19 in vulnerable low- and middle-income countries Health Interventions
Mozilla COVID-19 Open Source Solutions Fund Awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way. Tech Interventions
The COVID-19 High Performance Computing Consortium COVID-19 High Performance Computing (HPC) Consortium Sponsored by the White House Office of Science and Technology to aggregate computational resources for "extensive research in areas like bioinformatics, epidemiology, and molecular modeling to understand the threat we’re facing and form strategies to address it. Tech interventions
North Carolina Biotechnology Center Flash Grants To identify and energize the most creative ideas that exhibit early indications of commercial potential. Topics to be determined (posted by late September, 2020)
 3/10/21
 Commercial Development
PandemicTech PandemicTech Innovation Fellowship Projects that address the COVID-19 coronavirus given the timing of the PandemicTech Fellowship for 2020. rolling many
Amazon Web Services AWS Diagnostic Development Initiative (DDI) AWS is offering technical support and providing AWS promotional credits to support the use of AWS services to advance diagnostic research for selected institutions and companies. Resource
Ginko Bioworks Ginkgo Bioworks Partnerships Free platform access, connections to sources of funding, and R&D information sharing. Resource
23andMe 23andMe Research Innovation Collaborations Program The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort. rolling Resource
Other NIST Tools for Searching the Coronavirus Dataset New resources to allow researchers to get the most from the COVID-19 Open Research Dataset (CORD-19), a collection of scientific literature about coronaviruses containing tens of thousands of items. Resource
Other ICODA Tools For Researchers The International COVID-19 Data Alliance (ICODA) is a “Workbench” that allows researchers to discover, access and analyse global multi-dimensional datasets The platform will consolidate data and metadata from federated repositories to allow teams to work collectively on a focused research question. Data access and use is subject to rigorous data governance processes, based on the five safes framework. Resource
Other Meta A research discovery tool that uses machine learning to help researchers keep pace with discoveries through targeted feeds, maps both published papers and preprints — providing a single site to see them in one place. Resource
Other COVID-19 Open Research Dataset (CORD-19) Prepare and distribute a set of research literature about COVID-19, SARS-CoV-2, and the coronavirus group. Resource
Other Rapid Access for COVID-19 Research Department of Energy Basic Energy Sciences advanced neutron sources will provide remote rapid access to advanced user facilities to support research into the COVID-19 virus and the search for effective diagnostics and therapies. Facilities that will be made available at the Spallation Neutron Source (SNS) and High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory (ORNL), include neutron macromolecular crystallography, small-angle scattering, reflectometry, spectroscopy and imaging beamlines. Resource